MAM
RAPP

Meeder Asset Management’s Rapport Therapeutics RAPP Stock Holding History

Meeder Asset Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Buy
+2,774
New +$102K 0.01% 353
2026
Q1 		– Sell
-1,208
Closed -$36.7K – 1034
2025
Q4 		$36.7K Buy
+1,208
New +$33.4K ﹤0.01% 448

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Meeder Asset Management's RAPP Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 2,774 shares worth $116K. The stake represents 0.01% of the portfolio and ranks #353 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in RAPP as recently as Q4 2025.

Meeder Asset Management first reported a position in RAPP in Q4 2025 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Meeder Asset Management held 2,774 shares of Rapport Therapeutics worth $116K as of Q2 2026.
  • Rapport Therapeutics was a new Meeder Asset Management position in Q2 2026.
  • Rapport Therapeutics made up 0.01% of Meeder Asset Management's portfolio in Q2 2026, its #353 holding.
  • Meeder Asset Management first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.